Midazolam Nasal Spray (Nayzilam)

New Treatment for Seizure Clusters

What Is Midazolam Nasal Spray?

LGS is tough. Finding information shouldn’t be. That is why we provide information about this and other medications often used in LGS. We hope you find this information useful as you navigate your LGS journey.

Midazolam (generic name), also known as Nayzilam (the name brand), is a prescription medicine used for the short-term treatment of seizure clusters (also known as acute repetitive seizures). It is a rescue medication in the form of a nasal spray.

Watch Now: Learn about rescue medications for LGS, including Midazolam Nasal Spray

Presented by: Michael Chez, MD, Pediatric Epileptologist, Sutter Health, California

*Dr. Michael Chez is a Pediatric Epilepsy Expert and regularly treats LGS patients. This video was recorded in early 2022 at the request of the LGS Foundation to provide information to our family members about this medication. The Foundation does not endorse this or any product and is here only to provide information relevant to patient families. 

Additional Information:


NAYZILAM is a ready-to-use nasal spray that can be given by anyone, whenever seizure clusters occur.

The complete steps on how to use NAYZILAM are found in the full Instructions for Use


This video features step-by-step instructions on how to use the nasal spray device properly.

This information does not take the place of talking with your healthcare provider. If you have any questions about your condition or NAYZILAM, please speak with your healthcare provider or pharmacist.

LEARN MOREwww.nayzilam.com

The information here is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. The content provided is for informational purposes only. LGS Foundation is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options.

Updated: 2/20/2023